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Psoriasis is associated with chronic inflammatory skin
lesions that are characterized by epidermal hyperplasia,
impaired epidermal differentiation, and accumulation of
distinct leukocyte subpopulations. Largely considered to be
an autoimmune disease (though the autoantigen remains to
be identified), psoriasis has become the target of intense
immunological research interest, and of an increasing
number of immunosuppressive therapies. In contrast, the
vascular contribution to the pathogenesis of the disease has
traditionally received only limited attention, although cuta-
neous blood vessels show major abnormalities in psoriatic
lesions and are found to be enlarged, tortuous and
hyperpermeable (Braverman and Sibley, 1982). The angio-
genic stimulus is thought to be derived from the hyperplas-
tic epidermis, and, in 1994, vascular endothelial growth
factor (VEGF, also known as vascular permeability factor)
was identified as a major epidermis-derived vessel-specific
growth factor that was strongly up-regulated in psoriatic
skin lesions (Detmar et al, 1994). In this issue, Young et al
provide the first genetic evidence—based on the analysis
of single nucleotide polymorphisms of the VEGF gene in
psoriatic and in healthy individuals—that an ‘‘angiogenetic
constitution’’ might determine psoriasis susceptibility
(Young et al, 2004).
Several studies have demonstrated that VEGF expres-
sion is increased in lesional psoriatic skin, that the serum
levels of circulating VEGF protein are significantly elevated
in patients with severe disease, and that VEGF serum levels
were directly correlated with disease activity (Creamer et al,
1996; Bhushan et al, 1999; Creamer et al, 2002; Nielsen
et al, 2002). A major role of VEGF in the pathogenesis
of psoriasis was further corroborated by the phenotype of
transgenic mice with epidermis-specific overexpression of
VEGF. VEGF transgenic mice show enhanced skin vascu-
larity and vascular permeability (Detmar et al, 1998). At
about 6 months of age, these mice spontaneously develop
chronic inflammatory skin lesions that histologically closely
resemble human psoriasis (Xia et al, 2003). It is of interest
that selective targeting of skin vessels via epidermal
overexpression of an angiogenesis factor was able to
reproduce the complete psoriatic phenotype, including
epidermal hyperplasia and altered epidermal differentiation,
up-regulation of adhesion molecules, accumulation of CD4-
positive T-lymphocytes within the dermis and of CD8-
positive cells within the epidermis. Moreover, VEGF trans-
genic mice show the characteristic Koebner phenomenon,
with induction of chronic psoriasis-like lesions by unspecific
skin irritation (Xia et al, 2003).
VEGF is a homodimeric, heparin-binding glycoprotein
occurring in at least four isoforms of 121, 165, 189 and 201
amino acids, due to alternative splicing. The VEGF gene is
located on chromosome 6p.21, close to PSORS1, a major
psoriasis susceptibility locus (Trembath et al, 1997). VEGF
binds to two type III tyrosine kinase receptors that are
expressed predominantly on vascular endothelial cells, Flt-
1/VEGF receptor-1 (VEGFR-1) and KDR/Flk-1/VEGFR-2.
The expression of VEGF by keratinocytes is controlled
by distinct molecular mechanisms that include hypoxia-
inducible factors and several growth factors that mediate
epidermal hyperplasia, leading to paracrine induction of
cutaneous angiogenesis (Detmar, 2000). Individual VEGF
expression levels are also under genetic control. Whereas
no loss-of-function VEGF mutations have been found thus
far in humans (in mice, even the loss of one allele of the
VEGF gene leads to embryonic lethality), recent studies
indicate that distinct single nucleotide polymorphisms
(SNPs) of the VEGF gene are associated with reduced or
increased levels of circulating VEGF in normal individuals. In
particular, the G to C polymorphism at position þ 405
(numbered relative to the transcription initiation site; this
corresponds to position 643 relative to the translation
initiation site) within the leader sequence of the VEGF gene
enhances the activity of internal ribosomal entry site B
(IRES-B) and promotes the translation of large VEGF (L-
VEGF) isoforms at an alternative CUG1 codon (Huez et al,
2001; Lambrechts et al, 2003). These L-VEGF isoforms are
205 amino acid residues longer than the AUG initiated VEGF
isoforms and appear to increase the intracellular VEGF
protein pool. Proteolytic cleavage at their peptide signal
sequence leads to the conversion to the shorter secreted
VEGF isoforms. Within the normal population, the frequency
of the þ 405C allele is lower (approximately 30%) than that
of the G allele (approximately 70%).
In this issue, Young et al investigated two distinct SNPs
of the VEGF gene in 160 patients with type I chronic plaque
psoriasis and in 102 normal British controls (Young et al,
2004). They report that the þ 405C/C genotype of the VEGF
gene, and the þ 405C allele, were found significantly more
often in patients with severe psoriasis, as compared with
healthy control subjects. This genotype was also signifi-
cantly more frequent in psoriasis patients with disease
onset between the 20th and 40th year. Based on previous
reports that the þ405C allele is associated with elevated
serum levels of VEGF in healthy individuals (Watson et al,
2000), these findings indicate that distinct genetic poly-
morphisms might contribute to enhanced VEGF production
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and to individually increased psoriasis susceptibility. An-
other VEGF polymorphism (460 T to C) was significantly
less frequent in psoriasis patients with disease onset
between the 20th and 40th year; however, the impact of
the 460 T/T or T/C genotypes on VEGF production
remains at present unclear. In accordance with previous
reports, Young et al also found significantly enhanced VEGF
serum levels as well as increased levels of circulating
(soluble) VEGFR-1/Flt1 in psoriasis patients, although no
direct correlation with disease severity—as measured by
the PASI score—was found in this study.
Taken together, these results demonstrate—for the first
time—that distinct small nucleotide polymorphisms of the
VEGF gene occur more frequently in subsets of psoriasis
patients, and they suggest that these haplotypes may
contribute to the elevated VEGF levels observed in these
patients. Because of the increasing evidence that VEGF-
mediated activation of vascular endothelium plays a major
role in the pathogenesis of psoriasis, these findings further
suggest that the individual ‘‘angiogenetic constitution’’
determines disease susceptibility, similar to recent findings
in some other diseases (Awata et al, 2002; Lambrechts et al,
2003). One has to keep in mind, however, that the authors
studied a relatively small number of individuals and that
larger patient cohorts need to be investigated to confirm
and further detail the angiogenetic constitution in psoriasis.
Moreover, additional SNPs of the VEGF promoter have been
shown to influence systemic VEGF levels, and increasing
evidence indicates that combinations of SNPs are more
strongly associated with the level of VEGF production than
individual SNPs (Lambrechts et al, 2003). VEGF serum
levels were found to be more than 2-fold higher in normal
individuals with the (1,540/116/þ405) CGG/CGC geno-
type than in individuals with the AGG/AGG genotype
(Lambrechts et al, 2003), and further research is needed
to investigate the frequency of these and of other genotypic
variations in different psoriasis subtypes. However, environ-
mental changes also influence VEGF expression, and it is
conceivable that different VEGF haplotypes might be
associated with an enhanced local response to certain of
these stimuli (Koebner phenomenon). Together with the
biological evidence for a pathogenetic role of VEGF in
psoriasis, the study by Young et al suggests that VEGF acts
as a modifier gene in psoriasis and that therapeutic
blockade of the VEGF/VEGF receptor system might
represent a novel, pharmacogenomic approach for the
future treatment of psoriasis.
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